Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|January 1, 2008
- Applied Clinical Trials-01-01-2008
- Volume 0
- Issue 0
eShowcase: Oracle Initiatives Focus on Drug Safety
Recent announcements streamline adverse event reporting
Advertisement
Recent announcements streamline adverse event reporting
Oracle (Redwood Shores, CA) announced Safety in a Capsule, an IT and service collaboration between Oracle, Tata Consultancy Services (TCS), and DrugLogic. The offering combines Oracle's Siebel Contact Center Integration Pack for Oracle's Adverse Event Reporting (AER) System, DrugLogic's signal detection solution QScan, and TCS' Knowledge Process Outsourcing services to monitor and analyze pre- and postmarketing AER data for increased drug safety.
The Siebel Contact Center Integration Pack for the Oracle AER passes customer, product complaint, and potential AER information from the contact center to automatically load event-related information into the Oracle AER system. This solution works to reduce duplicate data entry, conflict resolution, and reconciliation. It is part of the Oracle Application Integration Architecture.
Oracle, (800) 672-2531,
Articles in this issue
almost 19 years ago
It's Official: CT Directive Poses Problemsalmost 19 years ago
Lights, Camera, Adaptionalmost 19 years ago
ACT Summit Highlights First-in-Man Trialsalmost 19 years ago
Changes and Challenges in the Year Aheadalmost 19 years ago
eShowcase: ClinicalAnalytics Version 4.0 Enhancedalmost 19 years ago
An Improved Trial Modelalmost 19 years ago
Tackling Racial Disparities in Researchalmost 19 years ago
Good Site and Sponsor Relationships Pay Offalmost 19 years ago
DIA Brings Canada's Best Togetheralmost 19 years ago
Two Decades of Change for PROsAdvertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
5